Floatz logo

Docetaxel

Myeloproliferative Neoplasms

Incyte CorporationSmall moleculePhase 2Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Myeloproliferative Neoplasms cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
OHSU Knight Cancer Institute
Phase 2BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
OHSU Knight Cancer Institute
Phase 2BB
Pembrolizumab
OHSU Knight Cancer Institute
Phase 1/2CCC
Pemigatinib
Incyte Corporation
Phase 1/2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Incyte Corporation
Phase 1/2CCC
Retifanlimab
Incyte Corporation
Phase 1/2CCC

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →